ArticleFrontiers in oncology2026
Investigating the impact of Sprouty-related EVH1 domain-containing protein 3 on gastric cancer prognosis and tumor microenvironments.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gastric cancer is a prevalent and lethal malignancy, yet effective biomarkers remain limited. SPRED3 has been implicated in other cancers, but its role in gastric cancer has remained completely unexplored. Methods: SPRED3 expression and clinical significance were analyzed using TCGA and GEO datasets. Knockdown experiments were performed in AGS and N87 gastric cancer cell lines to assess effects on proliferation (CCK-8), migration, and invasion (Transwell). Pathway changes were examined by Western blot and qRT-PCR. Immune infiltration was evaluated via CIBERSORT and TIDE algorithms, and drug sensitivity was predicted using GDSC database, with CETSA validating alpelisib-SPRED3 binding. Results: SPRED3 was significantly upregulated in gastric cancer tissues and cells, demonstrating diagnostic value (AUC = 0.794) and a significant association with poor prognosis. Knockdown of SPRED3 inhibited cell proliferation, migration, and invasion, and suppressed the MAPK and NF-κB pathways. SPRED3 expression correlated positively with M2 macrophage infiltration and immune checkpoints (PD-L1, CTLA-4), and negatively with CD8+ T cells and activated NK cells. High SPRED3 expression was associated with elevated tumor immune dysfunction and exclusion scores, indicating immune exclusion and poor immunotherapy response, whereas low SPRED3 expression predicted increased sensitivity to alpelisib. Discussion: Our results indicate that SPRED3 serves as a prognostic and immunological biomarker in gastric cancer. Conceptually, this study introduces SPRED3 as a previously unrecognized regulator in gastric cancer pathogenesis and immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.